Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
John Edelsberg, Derek Weycker, Mark Bensink, Charles Bowers & Gary H. Lyman. (2020) Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. Current Medical Research and Opinion 36:3, pages 483-495.
Read now
Read now
R. Andrew Harkins, Sharvil P. Patel & Christopher R. Flowers. (2019) Cost burden of diffuse large B-cell lymphoma. Expert Review of Pharmacoeconomics & Outcomes Research 19:6, pages 645-661.
Read now
Read now
Kelly Fust, Anju Parthan, Michael Maschio, Qing Gu, Xiaoyan Li, Gary H. Lyman, Spiros Tzivelekis, Guillermo Villa & Milton C. Weinstein. (2017) Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. Expert Review of Pharmacoeconomics & Outcomes Research 17:1, pages 39-52.
Read now
Read now
M. C. Cheung, A. Prica, J. Graczyk, R. Buckstein & K. K. W. Chan. (2016) Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis. Leukemia & Lymphoma 57:8, pages 1865-1875.
Read now
Read now
Gregory Hill, Richard Barron, Kelly Fust, Michelle E. Skornicki, Douglas C. A. Taylor, Milton C. Weinstein & Gary H. Lyman. (2014) Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses. Journal of Medical Economics 17:1, pages 32-42.
Read now
Read now
Jonathan Hoggatt & Louis M Pelus. (2014) New G-CSF agonists for neutropenia therapy. Expert Opinion on Investigational Drugs 23:1, pages 21-35.
Read now
Read now
H. J. Henk, L. Becker, H. Tan, J. Yu, A. Kavati, A. Naeim, R. Deeter & R. Barron. (2013) Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. Journal of Medical Economics 16:1, pages 160-168.
Read now
Read now
Russell Becker, Carole Dembek, Leigh Ann White & Louis P Garrison. (2012) The cost offsets and cost–effectiveness associated with pegylated drugs: a review of the literature. Expert Review of Pharmacoeconomics & Outcomes Research 12:6, pages 775-793.
Read now
Read now
Pierre Rofail, Mariam Tadros, Riham Ywakim, Mina Tadrous, Allison Krug & Leon E Cosler. (2012) Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia. Expert Review of Pharmacoeconomics & Outcomes Research 12:6, pages 699-709.
Read now
Read now
P. Swinburn, J. Wang, D. Chandiwana, W. Mansoor & A. Lloyd. (2012) Elicitation of health state utilities in neuroendocrine tumours. Journal of Medical Economics 15:4, pages 681-687.
Read now
Read now
Steven Simoens. (2009) Health economics of market access for biopharmaceuticals and biosimilars. Journal of Medical Economics 12:3, pages 211-218.
Read now
Read now
Articles from other publishers (41)
Yaqin Wang, Chenglong Zhao, Peizhi Ma & Dandan Jiang. (2023) Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study. Cancer Control 30, pages 107327482211402.
Crossref
Crossref
Girma Tekle Gebremariam, Atalay Mulu Fentie, Kebede Beyene, Beate Sander & Gebremedhin Beedemariam Gebretekle. (2022) Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. BMC Health Services Research 22:1.
Crossref
Crossref
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Aki Kato, Takahito Mizuno, Yoshio Miyake & Hitomi Teramachi. (2022) Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan. Supportive Care in Cancer 30:8, pages 6775-6783.
Crossref
Crossref
Paul Cornes, John Kelton, Rongzhe Liu, Omer Zaidi, Jennifer Stephens & Jingyan Yang. (2022) Real-world cost–effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia. Future Oncology 18:16.
Crossref
Crossref
Ramin Madanchi, Nils W. Engel, Winfried Alsdorf, Christoph Oing, Christian Frenzel, Finn-Ole Paulsen, Carsten Bokemeyer & Christoph Seidel. (2022) Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients. Bone Marrow Transplantation 57:5, pages 729-733.
Crossref
Crossref
Lauren Roder, Kelsey Konrardy, Dennis Grauer & Marc Hoffmann. (2021) Effects of filgrastim versus pegfilgrastim on outcomes of DA-R-EPOCH for non-Hodgkin’s lymphoma. Supportive Care in Cancer 29:9, pages 5075-5082.
Crossref
Crossref
Edward Li, Dylan J. Mezzio, David Campbell, Kim Campbell & Gary H. Lyman. (2021) Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncology Practice 17:8, pages e1235-e1245.
Crossref
Crossref
Jinma Ren, Carl V Asche, Yaping Shou & Aaron Galaznik. (2019) Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. Journal of Comparative Effectiveness Research 8:6, pages 393-402.
Crossref
Crossref
Sibylle Schirm, Christoph Engel, Sibylle Loibl, Markus Loeffler & Markus Scholz. (2017) Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. Journal of Cancer Research and Clinical Oncology 144:2, pages 343-358.
Crossref
Crossref
Prathima Reddy, Sandra Kanan, Andrew Cowan, Houston Warren, Brian Till, Mazyar Shadman, Ryan Cassaday, Oliver Press, Andrei Shustov, Ajay Gopal & Stephen D. Smith. (2017) Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. Clinical Lymphoma Myeloma and Leukemia 17:12, pages e87-e90.
Crossref
Crossref
Jew W. Kuan, Anselm T. Su & Chooi F. Leong. (2017) Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: A systematic review and meta-analysis. Journal of Clinical Apheresis 32:6, pages 517-542.
Crossref
Crossref
Kelly Fust, Xiaoyan Li, Michael Maschio, Guillermo Villa, Anju Parthan, Richard Barron, Milton C. Weinstein, Luc Somers, Caroline Hoefkens & Gary H. Lyman. (2016) Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. PharmacoEconomics 35:4, pages 425-438.
Crossref
Crossref
Craig R. Wright, Alister C. Ward & Aaron P. Russell. (2017) Granulocyte Colony-Stimulating Factor and Its Potential Application for Skeletal Muscle Repair and Regeneration. Mediators of Inflammation 2017, pages 1-9.
Crossref
Crossref
Ki Hyeong Lee, Ji-Yeon Kim, Moon Hee Lee, Hye Sook Han, Joo Han Lim, Keon Uk Park, In Hae Park, Eun Kyung Cho, So Young Yoon, Jee Hyun Kim, In Sil Choi, Jae Hoo Park, Young Jin Choi, Hee-Jun Kim, Kyung Hae Jung, Si-Young Kim, Do-Youn Oh & Seock-Ah Im. (2015) A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. Supportive Care in Cancer 24:4, pages 1709-1717.
Crossref
Crossref
Xiao Jun Wang, Tiffany Tang, Mohamad Farid, Richard Quek, Miriam Tao, Soon Thye Lim, Hwee Lin Wee & Alexandre Chan. (2016) Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. PLOS ONE 11:2, pages e0148901.
Crossref
Crossref
Jew-Win Kuan, Anselm Ting Su, Chooi-Fun Leong & Prathap Tharyan. (2016) Pegylated granulocyte colony stimulating factor versus non-pegylated granulocyte colony stimulating factor for peripheral stem cell mobilization. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Valentina Bozzoli, Maria C. Tisi, Elena Maiolo, Eleonora Alma, Silvia Bellesi, Francesco D'Alo’, Maria T. Voso, Giuseppe Leone & Stefan Hohaus. (2015)
Four doses of unpegylated
versus
one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma
. British Journal of Haematology 169:6, pages 787-794.
Crossref
Crossref
Esther K. Lee, William W. L. Wong, Maureen E. Trudeau & Kelvin K. W. Chan. (2015) Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. Breast Cancer Research and Treatment 150:1, pages 169-180.
Crossref
Crossref
Kelly Fust, Xiaoyan Li, Michael Maschio, Richard Barron, Milton C. Weinstein, Anju Parthan, Marjan Walli-Attaei, David B. Chandler & Gary H. Lyman. (2014) Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. Gynecologic Oncology 133:3, pages 446-453.
Crossref
Crossref
S. Barni, V. Lorusso, M. Giordano, G. Sogno, T. Gamucci, A. Santoro, R. Passalacqua, V. Iaffaioli, N. Zilembo, M. Mencoboni, M. Roselli, G. Pappagallo & P. Pronzato. (2013) A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Medical Oncology 31:1.
Crossref
Crossref
Frank G. Sandmann, Margreet G. Franken, Adri Steenhoek & Marc A. Koopmanschap. (2013) Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. Health Policy 112:3, pages 285-296.
Crossref
Crossref
S. A. Strassels, M. Dickson, L. B. Norris & C. L. Bennett. (2013) Primary Prophylaxis With Hematopoietic Colony Stimulating Factor: Insights From a Canadian Cost-Effectiveness Analysis. JNCI Journal of the National Cancer Institute 105:15, pages 1072-1073.
Crossref
Crossref
Nina Lathia, Pierre K. Isogai, Carlo De Angelis, Thomas J. Smith, Matthew Cheung, Nicole Mittmann, Jeffrey S. Hoch & Scott Walker. (2013) Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis Against Febrile Neutropenia in Lymphoma Patients. JNCI: Journal of the National Cancer Institute 105:15, pages 1078-1085.
Crossref
Crossref
Lionel Perrier, Anne Lefranc, David Pérol, Philippe Quittet, Aline Schmidt-Tanguy, Carole Siani, Christian de Peretti, Bertrand Favier, Pierre Biron, Philippe Moreau, Jacques Olivier Bay, Séverine Lissandre, Fabrice Jardin, Daniel Espinouse & Catherine Sebban. (2013) Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma. Applied Health Economics and Health Policy 11:2, pages 129-138.
Crossref
Crossref
Luciano J. Costa, Cindy Kramer, Kathy R. Hogan, Coleen D. Butcher, Amanda L. Littleton, Katie B. Shoptaw, Yubin Kang & Robert K. Stuart. (2012) Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion 52:11, pages 2375-2381.
Crossref
Crossref
Jew-Win Kuan, Anselm Ting Su & Chooi-Fun Leong. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Bernd C. Kieseier & Peter A. Calabresi. (2012) PEGylation of Interferon-β-1a. CNS Drugs 26:3, pages 205-214.
Crossref
Crossref
C. Sebban, A. Lefranc, L. Perrier, P. Moreau, D. Espinouse, A. Schmidt, L. Kammoun, H. Ghesquieres, C. Ferlay, J.O. Bay, S. Lissandre, D. Pérol, M. Michallet & P. Quittet. (2012) A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). European Journal of Cancer 48:5, pages 713-720.
Crossref
Crossref
Santosh Saraf & Howard Ozer. 2012. Twenty Years of G-CSF. Twenty Years of G-CSF
109
149
.
Bradford R. Hirsch & Gary H. Lyman. 2012. Twenty Years of G-CSF. Twenty Years of G-CSF
409
420
.
Jean Klastersky & Ahmad Awada. (2011) Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?. Critical Reviews in Oncology/Hematology 78:1, pages 17-23.
Crossref
Crossref
Jean A. Klastersky & Marianne Paesmans. (2011) Treatment of Febrile Neutropenia Is Expensive: Prevention Is the Answer. Onkologie 34:5, pages 226-228.
Crossref
Crossref
Gary H Lyman. (2011) A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. Current Opinion in Hematology 18:1, pages 1-10.
Crossref
Crossref
Jonathan C. Routh, Marc R. Laufer, Glenn M. Cannon, David A. Diamond & Patricio C. Gargollo. (2010) Management Strategies for Mayer-Rokitansky-Kuster-Hauser Related Vaginal Agenesis: A Cost-Effectiveness Analysis. Journal of Urology 184:5, pages 2116-2122.
Crossref
Crossref
Gary H. Lyman & Nicole M. Kuderer. 2011. Practical Geriatric Oncology. Practical Geriatric Oncology
323
337
.
Robert Rifkin, Gary Spitzer, Gregory Orloff, Romeo Mandanas, Dean McGaughey, Feng Zhan, Kristi A. Boehm, Lina Asmar & Roy Beveridge. (2010) Pegfilgrastim Appears Equivalent to Daily Dosing of Filgrastim to Treat Neutropenia After Autologous Peripheral Blood Stem Cell Transplantation in Patients With Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 10:3, pages 186-191.
Crossref
Crossref
Matti Aapro, Jeffrey Crawford & Didier Kamioner. (2010) Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?. Supportive Care in Cancer 18:5, pages 529-541.
Crossref
Crossref
Adi Eldar-Lissai & Gary H. Lyman. 2011. Hematopoietic Growth Factors in Oncology. Hematopoietic Growth Factors in Oncology
403
418
.
Zhimei Liu, Quan V. Doan, Jennifer Malin & Robert Leonar. (2012) The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Applied Health Economics and Health Policy 7:3, pages 193-205.
Crossref
Crossref
Gary H. Lyman, Anjana Lalla, Richard L. Barron & Robert W. Dubois. (2009) Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states. Clinical Therapeutics 31:5, pages 1092-1104.
Crossref
Crossref
. (2013) Pegfilgrastim worth it for preventing febrile neutropenia. PharmacoEconomics & Outcomes News 574:1, pages 7-7.
Crossref
Crossref